Emma Asma Cornwall
All posts from Emma Asma Cornwall
Emma Asma Cornwall in Gainers & Losers,

Biogen is finally doing better

Biogen (NASDAQ:BIIB) has jumped 5.6% into a trading halt as chatter centers on a potential takeout from Allergan (NYSE:AGN) or Merck (NYSE:MRK).

Biogen might not go for a deal, but the two suitors have tested the waters, the WSJ reports.The company's worth more than $68B, setting up what could be the sector's next blockbuster deal.

Well, Biogen shares has been trading poorly since last year and I was already at despair about this asset which has been in my long-term portfolio for couple of years, but finally thing are getting better for the company, and shares show bullish breakout: